Nuyten Dimitry SA - 23 Aug 2022 Form 4 Insider Report for Arcus Biosciences, Inc. (RCUS)

Role: Chief Medical Officer
Signature: /s/ Carolyn Tang, Attorney-in-Fact
Issuer symbol: RCUS
Transactions as of: 23 Aug 2022
Net transactions value: $0
Form type: 4
Filing time: 24 Aug 2022, 16:08:36 UTC
Previous filing: 08 Aug 2022
Next filing: 25 Jan 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RCUS	Common Stock	Award	$0	+42,500		$0.000000	42,500	23 Aug 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	RCUS	Stock Option (Right to Buy)	Award	$0	+170,000		$0.000000	170,000	23 Aug 2022	Common Stock	170,000	$26.00	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents the grant of restricted stock units that vest in four equal annual installments beginning September 15, 2023, subject to the Reporting Person's continued service to the Company.
F2	The option is exercisable in 48 equal monthly installments after August 1, 2022, subject to the Reporting Person's continued service to the Company.